Anticuerpo monoclonal anti-inmunoglobulina E en el tratamiento de la rinitis alérgica

allergic rhinitis (ar) is a disease with global high prevalence, its symptoms are directly related to environmental exposure to an allergen that triggers an inflammatory cascade mediated by immunoglobulin e. the current standard treatment of ar consists of environmental control, pharmacotherapy and immunotherapy; the recent emergence of monoclonal antibodies for the management of allergic diseases appears promising. studies have shown that omalizumab, an anti-ige humanized monoclonal antibody, is capable of modify the inflammatory ige-dependent response, becoming a possible alternative to the management of ar.